Evidence map›Paper›PMID 41426227›Full record

ArticleNAR molecular medicine2025

Gamma-retrovirus design for efficacious microRNA-mediated gene knock-down and protein co-expression without compromising titers.

Romain Vuillefroy de Silly, Bili Seijo, Jimmy Maillard, Patrick Reichenbach, Melita Irving

Abstract read
In one paragraph

Article in NAR molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Romain Vuillefroy de SillyLudwig Institute for Cancer Research, University of Lausanne and Department of Oncology, Lausanne University Hospital (CHUV), CH-1011 Lausanne, Switzerland.ORCID https://orcid.org/0000-0001-6573-9752
Bili SeijoLudwig Institute for Cancer Research, University of Lausanne and Department of Oncology, Lausanne University Hospital (CHUV), CH-1011 Lausanne, Switzerland.ORCID https://orcid.org/0000-0003-2479-6261
Jimmy MaillardLudwig Institute for Cancer Research, University of Lausanne and Department of Oncology, Lausanne University Hospital (CHUV), CH-1011 Lausanne, Switzerland.ORCID https://orcid.org/0009-0001-7471-7464
Patrick ReichenbachLudwig Institute for Cancer Research, University of Lausanne and Department of Oncology, Lausanne University Hospital (CHUV), CH-1011 Lausanne, Switzerland.
Melita IrvingLudwig Institute for Cancer Research, University of Lausanne and Department of Oncology, Lausanne University Hospital (CHUV), CH-1011 Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-6849-7194

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA interference (RNAi) is a powerful tool for controlling gene expression. Although stable gene down-regulation in cells can be achieved with viral vectors expressing short hairpin RNAs (shRNAs), incorporating shRNAs into a microRNA (miR) backbone can improve both the efficacy and safety of RNAi by exploiting the endogenous miR-processing machinery. For gamma-retroviral vectors there are two main strategies, LTR (Pol II)- and U6 (Pol III)-driven expression of the miR-based shRNA, but both have limitations in viral titers generated, knock-down efficacy, and/or protein/reporter gene co-expression levels. Here, we sought to evaluate the effectiveness of inserting miR-30a-based shRNA within the psi/packaging-containing intron of the murine stem cell virus (MSCV)-based splice-gag vector (MSGV) for which transcription is LTR-driven. Systematic comparison to previously described designs within the same viral backbone comprising a range of different shRNAs targets revealed maximal viral titer, knock-down and level of protein co-expression upon intronic insertion of miR-based shRNA. In addition, we demonstrated that the strategy can be extended to gene knock-down by wild-type miRs, as demonstrated for miR-30c1 and let-7a. Taken together, we have developed a gamma-retroviral vector design facilitating efficacious miR-mediated gene knock-down and maintaining strong viral titers.

Identifiers

PMID41426227
PMCPMC12715684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.